Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM)
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent desig
Biotechnologies, Pharmaceutique
2026-04-15 7:15 AM EDT | Yellowbird Diagnostics
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-14 10:00 AM EDT | Jones Healthcare Group
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa. The publication
Biotechnologies, Pharmaceutique
2026-04-14 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Telescope Innovations Provides Financial Results of Second Fiscal Quarter 2026
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended February 28, 2026 (Q2 FY2026). The Company generated revenues of approximately $1.6 million during this period, with strong contributions from the development a
Technologies, Produits chimiques, Pharmaceutique
2026-04-13 6:00 PM EDT | Telescope Innovations Corp.
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/0
Biotechnologies, Pharmaceutique
2026-04-13 8:00 AM EDT | PharmaTher Holdings Ltd.
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses has demonstrated a complete response of all animals treated with X-Ray-activated Rutherrin® in a preclinical animal model of M
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-13 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed both a non-brokered private placement offering ("Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-04-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Robert Bitterman, Chief Executive Officer and Chairman of the Board, will present at the Centri Capital Conference on Tuesday, April 14, 2026, at Nasdaq Marketsite in New York City. The present
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-09 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform
New Zealand and Kingston, Ontario--(Newsfile Corp. - April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon® automated cell therapy manufacturing platform. The collaboration bui
Biotechnologies, Pharmaceutique
2026-04-07 10:15 AM EDT | Octane Medical Group
Canadian Ophthalmologists Highlight Seasonal Environmental Risks to Eye Health
Ottawa, Ontario--(Newsfile Corp. - April 7, 2026) - Ophthalmologists across Canada are observing the impact of seasonal environmental exposures — including ultraviolet (UV) radiation, wildfire smoke, and airborne allergens — on patients' ocular health and visual comfort. As these factors intensify during the spring and summer months, the Canadian Ophthalmological Society (COS) is underscoring the importance of awareness and preventive care to reduce both immediate irritation and l
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Les ophtalmologistes canadiens mettent en garde contre les risques environnementaux saisonniers pour la santé oculaire
Ottawa, Ontario--(Newsfile Corp. - 7 avril 2026) - Partout au pays, les ophtalmologistes constatent les effets des expositions environnementales saisonnières, notamment le rayonnement ultraviolet (UV), la fumée des feux de forêt et les allergènes en suspension dans l'air - sur la santé oculaire et le confort visuel des patients. À mesure que ces facteurs s'intensifient au printemps et à l'été, la Société canadienne d'ophtalmologie (SCO) s
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-07 7:30 AM EDT | Canadian Ophthalmological Society (COS)
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (the "Company"), today announced that it has closed on a private placement providing up to $24 million in gross proceeds, consisting of $5.0 million in upfront funding and up to an additional $19 million upon the exercise of accompanying milestone-based warrants. The sole investors in the private placement are Perceptive Advisors and ADAR1 Capital Management. No placement agent was engaged in
Biotechnologies, Pharmaceutique
2026-04-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product
Highlights Brazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026 Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with applia
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-04-07 7:00 AM EDT | TempraMed Technologies Ltd.
Kiora Pharmaceuticals Announces Management Team Changes
Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D., MBA, will depart from his role as Chief Development Officer on April 17, 2026, to pursue other opportunities. The Company has initiated a search for his successor. "Eric has made many important contributions to Kiora during his time with the Company," said Brian M. Strem, Ph.D., President and Chief Executive Officer
Biotechnologies, Pharmaceutique
2026-04-02 4:30 PM EDT | Kiora Pharmaceuticals, Inc.
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative o
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-02 8:00 AM EDT | Elite Pharmaceuticals, Inc.
PreveCeutical Adopts Semi-Annual Financial Reporting
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi
Biotechnologies, Pharmaceutique, Santé
2026-04-01 4:00 PM EDT | PreveCeutical Medical Inc.
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc.
Biotechnologies, Pharmaceutique, Santé
2026-03-31 4:02 PM EDT | BioHarvest Sciences Inc.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program is being conducted under a contract sig
Biotechnologies, Pharmaceutique, Santé
2026-03-31 8:00 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.